ViiV Healthcare: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''ViiV Healthcare''' is a global specialist HIV | {{DISPLAYTITLE:ViiV Healthcare}} | ||
[[File:ViiV_Healthcare_logo_2023.png|thumb|right|ViiV Healthcare logo, 2023]] | |||
'''ViiV Healthcare''' is a global specialist [[pharmaceutical company]] focused on the development and commercialization of medicines to treat [[HIV/AIDS]]. Established in 2009, ViiV Healthcare is a joint venture between [[GlaxoSmithKline]], [[Pfizer]], and [[Shionogi]]. The company is headquartered in [[Brentford]], [[United Kingdom]]. | |||
==History== | ==History== | ||
ViiV Healthcare was | ViiV Healthcare was formed to address the unmet needs of people living with HIV/AIDS. The joint venture combined the HIV portfolios of GlaxoSmithKline and Pfizer, with Shionogi joining later in 2012. Since its inception, ViiV Healthcare has been dedicated to researching and developing new treatments for HIV, as well as improving access to these treatments worldwide. | ||
==Products== | ==Products== | ||
ViiV Healthcare | ViiV Healthcare offers a range of antiretroviral medications used in the treatment of HIV. Some of the key products include: | ||
* '''[[Dolutegravir]]''' - An [[integrase inhibitor]] used in combination with other antiretroviral agents. | |||
* '''[[Abacavir]]''' - A [[nucleoside reverse transcriptase inhibitor]] (NRTI) used in combination therapy. | |||
* '''[[Lamivudine]]''' - Another NRTI often used in combination with other antiretrovirals. | |||
The company continues to invest in research and development to bring new and innovative treatments to market. | |||
==Research and Development== | ==Research and Development== | ||
ViiV Healthcare is committed to advancing | ViiV Healthcare is committed to advancing the science of HIV treatment and prevention. The company invests significantly in [[clinical trials]] and collaborates with various research institutions and organizations to develop new therapies. ViiV Healthcare's research focuses on improving the efficacy, safety, and tolerability of HIV treatments, as well as exploring new mechanisms of action. | ||
==Community | ==Global Access and Community Initiatives== | ||
ViiV Healthcare is | ViiV Healthcare is dedicated to improving access to HIV treatments in low- and middle-income countries. The company has established several initiatives to reduce the cost of medications and support healthcare infrastructure in these regions. ViiV Healthcare also collaborates with non-governmental organizations and community groups to enhance awareness and education about HIV prevention and treatment. | ||
== | ==Partnerships== | ||
ViiV Healthcare works closely with a variety of partners, including academic institutions, non-profit organizations, and other pharmaceutical companies, to advance HIV research and improve patient outcomes. These partnerships are crucial for the development of new therapies and the expansion of access to existing treatments. | |||
==Related pages== | |||
* [[HIV/AIDS]] | |||
* [[Antiretroviral drug]] | |||
* [[GlaxoSmithKline]] | * [[GlaxoSmithKline]] | ||
* [[Pfizer]] | * [[Pfizer]] | ||
* [[Shionogi]] | * [[Shionogi]] | ||
[[Category:Pharmaceutical companies]] | [[Category:Pharmaceutical companies]] | ||
[[Category:HIV/AIDS]] | [[Category:HIV/AIDS organizations]] | ||
[[Category: | [[Category:Companies established in 2009]] | ||
Latest revision as of 05:58, 16 February 2025
ViiV Healthcare is a global specialist pharmaceutical company focused on the development and commercialization of medicines to treat HIV/AIDS. Established in 2009, ViiV Healthcare is a joint venture between GlaxoSmithKline, Pfizer, and Shionogi. The company is headquartered in Brentford, United Kingdom.
History[edit]
ViiV Healthcare was formed to address the unmet needs of people living with HIV/AIDS. The joint venture combined the HIV portfolios of GlaxoSmithKline and Pfizer, with Shionogi joining later in 2012. Since its inception, ViiV Healthcare has been dedicated to researching and developing new treatments for HIV, as well as improving access to these treatments worldwide.
Products[edit]
ViiV Healthcare offers a range of antiretroviral medications used in the treatment of HIV. Some of the key products include:
- Dolutegravir - An integrase inhibitor used in combination with other antiretroviral agents.
- Abacavir - A nucleoside reverse transcriptase inhibitor (NRTI) used in combination therapy.
- Lamivudine - Another NRTI often used in combination with other antiretrovirals.
The company continues to invest in research and development to bring new and innovative treatments to market.
Research and Development[edit]
ViiV Healthcare is committed to advancing the science of HIV treatment and prevention. The company invests significantly in clinical trials and collaborates with various research institutions and organizations to develop new therapies. ViiV Healthcare's research focuses on improving the efficacy, safety, and tolerability of HIV treatments, as well as exploring new mechanisms of action.
Global Access and Community Initiatives[edit]
ViiV Healthcare is dedicated to improving access to HIV treatments in low- and middle-income countries. The company has established several initiatives to reduce the cost of medications and support healthcare infrastructure in these regions. ViiV Healthcare also collaborates with non-governmental organizations and community groups to enhance awareness and education about HIV prevention and treatment.
Partnerships[edit]
ViiV Healthcare works closely with a variety of partners, including academic institutions, non-profit organizations, and other pharmaceutical companies, to advance HIV research and improve patient outcomes. These partnerships are crucial for the development of new therapies and the expansion of access to existing treatments.
